Loading
ONE-D TMS protocol and d-cycloserine (125 mg) / Concussion / Depression · Phase 2/3 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registration for an optimized neuroplasticity-enhanced TMS protocol combined with d-cycloserine in female athletes with concurrent depression and concussion. The study has not yet begun recruitment and no efficacy or safety results are available; it remains in the planning phase.
Phase 2/3, Interventional, Single Group, Open label, Treatment purpose. Concussion, Depression; Female; age from 18 Years; to 65 Years. Intervention: Female athletes with a history of concussion and depression. n = 35. 1 site: United States.
This is a clinical trial registration for an optimized neuroplasticity-enhanced TMS protocol combined with d-cycloserine in female athletes with concurrent depression and concussion. The study has not yet begun recruitment and no efficacy or safety results are available; it remains in the planning phase.
This is a registry record with no posted results; no efficacy, safety, or outcome data are available.
This study is in early planning stages and cannot yet inform clinical practice. If successfully completed, results comparing ONE-D TMS plus d-cycloserine to a control could potentially inform a new treatment approach for the under-researched intersection of sports concussion and depression in female athletes.
This is a Phase 2/3 trial registration with no posted results; the study is not yet recruiting and outcome data are unavailable, making it an early-stage intervention feasibility record rather than evidence of efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This study is in early planning stages and cannot yet inform clinical practice. If successfully completed, results comparing ONE-D TMS plus d-cycloserine to a control could potentially inform a new treatment approach for the under-researched intersection of sports concussion and depression in female athletes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07507214). This is a study registration, not published results. Lead sponsor: University of Florida. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 35 participants (ESTIMATED). Conditions: Concussion, Depression. Interventions: DEVICE: ONE-D TMS protocol and d-cycloserine (125 mg). Primary outcome measures: Patient Health Questionnaire 9 (PHQ-9) depression symptom inventory scores , Baseline, 12 weeks; Sport Mental Health Assessment Tool 1 (SMHAT-1) depression symptom inventory scores , Baseline, 3 weeks, 6 weeks, 12 weeks. Brief summary: Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.